NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 412)
Posted On: 02/26/2018 5:34:30 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Appoints Director of International Operations
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its appointment of Dr. Maher Khaled to the position of director of international operations. Khaled bolsters the PreveCeutical team with more than a decade of experience in commercializing therapeutic and diagnostic technologies, most recently at UniQuest Pty Ltd. Moving forward, he will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the company’s ongoing operations in Australia, reviewing acquisition and licensing opportunities and leading commercialization efforts for its growing IP portfolio. “We are delighted to have Dr. Khaled as part of our team,” Stephen Van Deventer, chairman and CEO of PreveCeutical, stated in the news release. “Dr. Khaled’s degrees in law and science, as well as his experience in commercialising therapeutic and diagnostic technologies will be of tremendous benefit to PreveCeutical and its shareholders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its appointment of Dr. Maher Khaled to the position of director of international operations. Khaled bolsters the PreveCeutical team with more than a decade of experience in commercializing therapeutic and diagnostic technologies, most recently at UniQuest Pty Ltd. Moving forward, he will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the company’s ongoing operations in Australia, reviewing acquisition and licensing opportunities and leading commercialization efforts for its growing IP portfolio. “We are delighted to have Dr. Khaled as part of our team,” Stephen Van Deventer, chairman and CEO of PreveCeutical, stated in the news release. “Dr. Khaled’s degrees in law and science, as well as his experience in commercialising therapeutic and diagnostic technologies will be of tremendous benefit to PreveCeutical and its shareholders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)